Biotechnology
Commented by Carsten Mainitz on December 23rd, 2025 | 08:45 CET
USD 600 billion market potential – Pfizer and Bayer are in the race, Vidac Pharma in the fast lane?
The market for cancer drugs is the largest segment within the pharmaceutical industry and currently has a volume of over USD 200 billion. According to experts, the market will already be worth USD 500 to 600 billion by 2032 or 2033. Companies such as Pfizer and Bayer are among the industry leaders. As is often the case, however, there are promising stocks from the second and third tiers beyond the blue chips. One such company is Vidac Pharma. The Company is pursuing a new, promising approach to skin cancer. Analysts attest to the shares' great potential.
Read
Commented by Fabian Lorenz on December 23rd, 2025 | 07:35 CET
Big news at the turn of the year! Nordex, Novo Nordisk, AJN Resources!
Is now the time for gold explorers? The price of gold remains firmly above USD 4,300 per ounce, and shares of gold producers are performing well, perhaps even a little too well. Investors looking to continue participating in the gold bull market may therefore turn their attention to exploration companies. One such candidate is AJN Resources. The stock has already moved higher, yet still offers upside potential, supported by takeover speculation. Novo Nordisk has submitted an application for US approval following convincing Phase 3 results, a step that would be strategically significant for the Company. Meanwhile, Nordex remains one of the positive surprises of 2025, having reported another major order. The key question now is how far can the rally go?
Read
Commented by André Will-Laudien on December 18th, 2025 | 07:20 CET
Turnaround with a 100% chance in 2026! Novo Nordisk, TeamViewer, Equinox, and Laurion Mineral on the launch pad
The 2025 stock market year did not go well for everyone involved. The stocks in our selection today can tell us a thing or two about how it feels to be at the bottom of the rankings. But sometimes the stock market gets it wrong, because although Novo Nordisk has issued three profit warnings, the Company is still making good money. The situation is similar at TeamViewer, where there have been some disappointments in terms of growth, but the EBIT margin is still above 30%. It is completely incomprehensible that Laurion Minerals is at the bottom of the chart compared to other explorers. The drill results from Ontario show good mineralization values in gold not far from Equinox's Greenstone Mine. With gold prices at USD 4,300, the stock should soon see a surge. We do the math.
Read
Commented by Carsten Mainitz on December 17th, 2025 | 07:35 CET
Winners for 2026: RZOLV Technologies, Evotec, Mutares have what it takes – which developments are crucial?
The 2025 stock market year was full of exciting developments. Bull markets in commodities, interest rate cuts, and geopolitical tensions. However, some companies, such as Evotec, had to deal with many home-grown problems and lagged behind the positive performance of the overall market. Mutares saw its coffers fill up, but its share price could have done better this year. Next year could be very successful for RZOLV Technologies. The Canadians are solving a major problem in gold mining.
Read
Commented by Fabian Lorenz on December 16th, 2025 | 07:15 CET
Novo Nordisk makes a statement! TUI shares jump! Globex shares strong!
Novo Nordisk can end the horror year of 2025 on a positive note. The EMA has issued a positive opinion on a higher Wegovy dosage. Sales could start as early as January. Globex Mining shares have gained over 35% in the current year. There is much to suggest that the share price will continue to rise. With Globex Mining, investors benefit from the commodities boom in a legally secure region with diversified risk. The tourism boom could soon be over, given the economic development in Europe. These prospects dragged down the shares of TUI. However, the stock has reacted strongly in recent days.
Read
Commented by Fabian Lorenz on December 15th, 2025 | 07:25 CET
Alarm bells ringing at Evotec! BioNTech and Vidac Pharma achieve success in the fight against cancer! Analysts recommend buying!
Alarm bells are ringing at Evotec. A major shareholder has completely withdrawn from the German biotech company. The security is trading at 2016 levels. Vidac Pharma, on the other hand, has reached a milestone. In the EU, the Phase 2b clinical trial for the ointment Tuvatexib (VDA1102) against a particularly active, fast-growing precursor of skin cancer can begin. BioNTech is also continuing the fight against cancer. Initial results from the global Phase 2 trial of the non-specific antibody candidate Pumitamig showed encouraging anti-tumor activity in advanced triple-negative breast cancer. Analysts recommend buying shares in Vidac and BioNTech.
Read
Commented by Carsten Mainitz on December 11th, 2025 | 07:20 CET
On the winning side – now and in 2026: Antimony Resources and Bayer, crash at Evotec!
The year 2025 is drawing to a close. It is time to focus on stocks and investment themes that could offer attractive returns in 2026. Trends such as AI, defense, and robotics are expected to continue. Further involvement in the commodities sector also appears lucrative. Here, investors can find an exciting second-tier investment story in the still largely undiscovered Canadian company Antimony Resources. But opportunities also exist in the blue-chip segment. Bayer has established a solid foundation this year, and analysts have recently raised their price targets significantly. For heavily punished stocks like Evotec, a turnaround could also emerge next year.
Read
Commented by Nico Popp on December 9th, 2025 | 07:05 CET
Attacking the fuel that feeds tumors: Why Roche, Pfizer, and Vidac Pharma are redefining oncology
Modern cancer therapy is no longer about blunt-force attacks, but rather precise, targeted interventions. While oncology in recent decades has been dominated by non-specific cell toxins, today's research resembles surgical intervention in the biological software of a disease. Industry heavyweights, Roche and Pfizer, are securing their market positions with gigantic portfolios of immunotherapies. But away from the corporate headquarters of Basel and New York, agile biotech pioneers are working on approaches that attack the very foundation of cancer cells: their energy supply. Those who pull the plug on cancer cells could be among the big winners in the biotech sector in 2026.
Read
Commented by Fabian Lorenz on December 8th, 2025 | 07:15 CET
RENK better than HENSOLDT? Risk at NOVO NORDISK! Billion-dollar opportunity with RZOLV Technologies!?
Is RENK's stock better than Hensoldt's? That is what analysts are saying. According to them, the transmission specialist is attractively valued at the current level. Hensoldt, on the other hand, is having problems converting its order backlog into revenue growth, leading to a significant reduction in its price target. In contrast, RZOLV Technologies shares have enormous upside potential. The Company aims to replace a toxic chemical used in gold extraction, thereby opening up a billion-dollar market. Development is nearly complete, and patents have been filed. In just a few months, RZOLV could become a hot takeover candidate. Meanwhile, takeovers currently appear to be a way for Novo Nordisk to replenish its drug pipeline, with the Danish company taking risks worth billions - Pfizer, take note.
Read
Commented by Armin Schulz on December 8th, 2025 | 07:15 CET
Leveraging AI revenue potential: The master plan from Novo Nordisk, Aspermont, and Deutsche Telekom
Artificial intelligence is permeating the economy and creating an unprecedented productivity boost. Efficiency gains of 25% in manufacturing and savings of one trillion dollars by 2030 in supply chains are just the beginning. This growth potential of up to 0.8 percentage points per year leverages the profitability of pioneers and clearly separates them from the rest of the market. Who are the pioneers who are already applying this disruptive force today and will translate it into concrete profits in the future? Three companies are leading the way: Novo Nordisk, Aspermont, and Deutsche Telekom.
Read